NOTTINGHAM, England--(BUSINESS WIRE)--Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards ...
Two technologies that are based on research by University of Nottingham experts to reduce the severity of tics in people with Tourette syndrome (TS) are closer to patient use after being recommended ...
Neupulse, a neurotherapeutics company developing solutions for brain health conditions such as Tourette's syndrome, has raised £3m to accelerate its path to market. The funding round was led by Eos ...
Add Yahoo as a preferred source to see more of our stories on Google. "Best feeling in the world @Neupulse," she captioned the update. In the clip, Baylen and her family sat in their living room while ...
The National Institute for Health and Care Excellence (NICE) has approved two technologies for treating chronic tic disorders and Tourette syndrome. The Online Remote Behavioural Intervention for Tics ...
A new wrist device to help control Tourette’s Syndrome is a step closer to being commercialised after University of Nottingham spin-out company Neupulse raised almost £1m in additional funding.
Biopharma and med-tech companies raising money in public or private financings, including: Berlin Heals, Biorestorative, Entirety, Nektar, Neupulse, Neurent, Xilio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results